FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W4361953770> ?p ?o ?g. }

• W4361953770 abstract "<div>AbstractPurpose:<p>As hypoxia can mediate resistance to immunotherapy, we investigated the safety, tolerability, and efficacy of combining evofosfamide, a prodrug that alleviates hypoxia, with ipilimumab, an immune checkpoint inhibitor, in immunologically “cold” cancers, which are intrinsically insensitive to immunotherapy, as well as in “hot/warm” metastatic cancers that are, atypical of such cancers, resistant to immunotherapy.</p>Patients and Methods:<p>In a phase I, 3+3 dose-escalation trial (NCT03098160), evofosfamide (400–640 mg/m²) and ipilimumab (3 mg/kg) were administered in four 3-week cycles. The former was administered on days 1 and 8 of cycles 1–2, while the latter was administered on day 8 of cycles 1–4. Response was assessed using immune-related RECIST and retreatment was allowed, if deemed beneficial, after completion of cycle 4 or at progression.</p>Results:<p>Twenty-two patients were enrolled, of whom 21 were evaluable, encompassing castration-resistant prostate cancer (<i>n</i> = 11), pancreatic cancer (<i>n</i> = 7), immunotherapy-resistant melanoma (<i>n</i> = 2), and human papillomavirus–negative head and neck cancer (<i>n</i> = 1). Drug-related hematologic toxicities, rash, fever, nausea, vomiting, and elevation of liver enzymes were observed in > 10% of patients. The most common drug-related grade 3 adverse event was alanine aminotransferase elevation (33.3%). Two patients discontinued ipilimumab and 4 required evofosfamide deescalation due to toxicity. Of 18 patients with measurable disease at baseline, 3 (16.7%) achieved partial response and 12 (66.7%) achieved stable disease. The best responses were observed at 560 mg/m² evofosfamide. Preexisting immune gene signatures predicted response to therapy, while hypermetabolic tumors predicted progression. Responders also showed improved peripheral T-cell proliferation and increased intratumoral T-cell infiltration into hypoxia.</p>Conclusions:<p>No new or unexpected safety signals were observed from combining evofosfamide and ipilimumab, and evidence of therapeutic activity was noted.</p></div>" @default.
• W4361953770 created "2023-04-05" @default.
• W4361953770 creator A5008786567 @default.
• W4361953770 creator A5013704079 @default.
• W4361953770 creator A5016328953 @default.
• W4361953770 creator A5019520358 @default.
• W4361953770 creator A5021303778 @default.
• W4361953770 creator A5022841891 @default.
• W4361953770 creator A5026095888 @default.
• W4361953770 creator A5026538331 @default.
• W4361953770 creator A5031165814 @default.
• W4361953770 creator A5031591028 @default.
• W4361953770 creator A5040118284 @default.
• W4361953770 creator A5043675371 @default.
• W4361953770 creator A5045197829 @default.
• W4361953770 creator A5052755605 @default.
• W4361953770 creator A5056684214 @default.
• W4361953770 creator A5065861312 @default.
• W4361953770 creator A5068368047 @default.
• W4361953770 creator A5073135717 @default.
• W4361953770 creator A5076426660 @default.
• W4361953770 creator A5079779850 @default.
• W4361953770 creator A5082283107 @default.
• W4361953770 creator A5084349853 @default.
• W4361953770 creator A5084812789 @default.
• W4361953770 creator A5084919080 @default.
• W4361953770 creator A5089753814 @default.
• W4361953770 date "2023-03-31" @default.
• W4361953770 modified "2023-10-06" @default.
• W4361953770 title "Data from A Phase I Dose-Escalation Study to Evaluate the Safety and Tolerability of Evofosfamide in Combination with Ipilimumab in Advanced Solid Malignancies" @default.
• W4361953770 doi "https://doi.org/10.1158/1078-0432.c.6530310.v1" @default.
• W4361953770 hasPublicationYear "2023" @default.
• W4361953770 type Work @default.
• W4361953770 citedByCount "0" @default.
• W4361953770 crossrefType "posted-content" @default.
• W4361953770 hasAuthorship W4361953770A5008786567 @default.
• W4361953770 hasAuthorship W4361953770A5013704079 @default.
• W4361953770 hasAuthorship W4361953770A5016328953 @default.
• W4361953770 hasAuthorship W4361953770A5019520358 @default.
• W4361953770 hasAuthorship W4361953770A5021303778 @default.
• W4361953770 hasAuthorship W4361953770A5022841891 @default.
• W4361953770 hasAuthorship W4361953770A5026095888 @default.
• W4361953770 hasAuthorship W4361953770A5026538331 @default.
• W4361953770 hasAuthorship W4361953770A5031165814 @default.
• W4361953770 hasAuthorship W4361953770A5031591028 @default.
• W4361953770 hasAuthorship W4361953770A5040118284 @default.
• W4361953770 hasAuthorship W4361953770A5043675371 @default.
• W4361953770 hasAuthorship W4361953770A5045197829 @default.
• W4361953770 hasAuthorship W4361953770A5052755605 @default.
• W4361953770 hasAuthorship W4361953770A5056684214 @default.
• W4361953770 hasAuthorship W4361953770A5065861312 @default.
• W4361953770 hasAuthorship W4361953770A5068368047 @default.
• W4361953770 hasAuthorship W4361953770A5073135717 @default.
• W4361953770 hasAuthorship W4361953770A5076426660 @default.
• W4361953770 hasAuthorship W4361953770A5079779850 @default.
• W4361953770 hasAuthorship W4361953770A5082283107 @default.
• W4361953770 hasAuthorship W4361953770A5084349853 @default.
• W4361953770 hasAuthorship W4361953770A5084812789 @default.
• W4361953770 hasAuthorship W4361953770A5084919080 @default.
• W4361953770 hasAuthorship W4361953770A5089753814 @default.
• W4361953770 hasBestOaLocation W43619537702 @default.
• W4361953770 hasConcept C121608353 @default.
• W4361953770 hasConcept C126322002 @default.
• W4361953770 hasConcept C143998085 @default.
• W4361953770 hasConcept C197934379 @default.
• W4361953770 hasConcept C2776694085 @default.
• W4361953770 hasConcept C2777063308 @default.
• W4361953770 hasConcept C2777701055 @default.
• W4361953770 hasConcept C2778375690 @default.
• W4361953770 hasConcept C2780192828 @default.
• W4361953770 hasConcept C2781433595 @default.
• W4361953770 hasConcept C71924100 @default.
• W4361953770 hasConcept C90924648 @default.
• W4361953770 hasConceptScore W4361953770C121608353 @default.
• W4361953770 hasConceptScore W4361953770C126322002 @default.
• W4361953770 hasConceptScore W4361953770C143998085 @default.
• W4361953770 hasConceptScore W4361953770C197934379 @default.
• W4361953770 hasConceptScore W4361953770C2776694085 @default.
• W4361953770 hasConceptScore W4361953770C2777063308 @default.
• W4361953770 hasConceptScore W4361953770C2777701055 @default.
• W4361953770 hasConceptScore W4361953770C2778375690 @default.
• W4361953770 hasConceptScore W4361953770C2780192828 @default.
• W4361953770 hasConceptScore W4361953770C2781433595 @default.
• W4361953770 hasConceptScore W4361953770C71924100 @default.
• W4361953770 hasConceptScore W4361953770C90924648 @default.
• W4361953770 hasLocation W43619537701 @default.
• W4361953770 hasLocation W43619537702 @default.
• W4361953770 hasOpenAccess W4361953770 @default.
• W4361953770 hasPrimaryLocation W43619537701 @default.
• W4361953770 hasRelatedWork W1997832483 @default.
• W4361953770 hasRelatedWork W2003086854 @default.
• W4361953770 hasRelatedWork W2051146169 @default.
• W4361953770 hasRelatedWork W2064686787 @default.
• W4361953770 hasRelatedWork W2087016115 @default.
• W4361953770 hasRelatedWork W2567294122 @default.
• W4361953770 hasRelatedWork W3029766637 @default.
• W4361953770 hasRelatedWork W3215044659 @default.
• W4361953770 hasRelatedWork W4386083912 @default.
• W4361953770 hasRelatedWork W3120888088 @default.
• W4361953770 isParatext "false" @default.

• next